Erratum
for
O'Brien et al., J Clin Oncol 25 (9) 1114-1120.
Journal of Clinical Oncology, Vol 26, No 5 (February 10), 2008: pp. 820-a
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.15.8030
ERRATA
The March 20, 2007, article by O'Brien et al, entitled "Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia" (J Clin Oncol 25:1114-1120, 2007) contained errors.
In the Authors' Disclosures of Potential Conflicts of Interest section, the following additional relationships should have been disclosed for Susan O'Brien:
Consultant: Genta
Research Funds: Bristol-Myers Squibb, Eli Lilly, Gemin X, Novartis
|